180 Life Sciences Announces An Agreement For A Clinical Pharmacology Study Testing A New Formulation Of CBD For Enhanced Oral Uptake
Portfolio Pulse from Benzinga Newsdesk
180 Life Sciences has announced an agreement for a clinical pharmacology study testing a new formulation of CBD for enhanced oral uptake. This could potentially lead to new product developments and revenue streams for the company.
August 07, 2023 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
180 Life Sciences' new agreement for a clinical study on a new CBD formulation could potentially lead to new product developments and revenue streams for the company.
The announcement of a new clinical study indicates that 180 Life Sciences is actively working on product development, which could potentially lead to new revenue streams. This is likely to be viewed positively by investors, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100